Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ bispecific Ziihera—at least according to two experts. More: Jazz touts Ziihera as the new HER2 agent of choice in
read moreM+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor. More: M+C Saatchi taps former Pfizer CMO Freda Lewis-Hall as 1st medical advisor Source: fierce
read more
First‑in‑class SK ion channel inhibitor enters next stage of clinical development More: Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation Source: News
read more
Company aims to expand treatment options for relapsed or refractory multiple myeloma More: Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination Source: News
read moreAll together, the top 10 spenders shelled out $285.8 million to air their TV drug ads throughout December. More: J&J’s Tremfya outstrips AbbVie’s Skyrizi again, closing out 2025 as December’s top TV ad spender Source: fierce
read moreWhile policy shifts and leadership shakeups at institutions like the FDA dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on what they do best—developing novel medicines to address unmet needs. More: 3
read more© 1994 - 2026 B.M. Pharmaceuticals